vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Postal Realty Trust, Inc. (PSTL). Click either name above to swap in a different company.
Postal Realty Trust, Inc. is the larger business by last-quarter revenue ($26.0M vs $21.9M, roughly 1.2× Cue Biopharma, Inc.). Postal Realty Trust, Inc. runs the higher net margin — 17.9% vs 7.2%, a 10.6% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 21.7%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 22.6%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Postal Realty Trust, Inc. is a specialized real estate investment trust that acquires, owns, and manages properties primarily leased to the United States Postal Service. Its portfolio includes last-mile postal facilities, sorting centers, and retail post office locations across the U.S., supporting critical mail and package delivery infrastructure.
CUE vs PSTL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $26.0M |
| Net Profit | $1.6M | $4.6M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | 39.2% |
| Net Margin | 7.2% | 17.9% |
| Revenue YoY | 1292.3% | 21.7% |
| Net Profit YoY | 116.7% | 3.1% |
| EPS (diluted) | $0.05 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $26.0M | ||
| Q3 25 | $2.1M | $24.3M | ||
| Q2 25 | $3.0M | $23.4M | ||
| Q1 25 | $421.0K | $22.1M | ||
| Q4 24 | $1.6M | $21.4M | ||
| Q3 24 | $3.3M | $19.7M | ||
| Q2 24 | $2.7M | $18.1M | ||
| Q1 24 | $1.7M | $17.3M |
| Q4 25 | $1.6M | $4.6M | ||
| Q3 25 | $-7.4M | $3.8M | ||
| Q2 25 | $-8.5M | $3.6M | ||
| Q1 25 | $-12.3M | $2.1M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $-8.7M | $1.1M | ||
| Q2 24 | $-10.2M | $817.0K | ||
| Q1 24 | $-12.3M | $206.0K |
| Q4 25 | 9.0% | 39.2% | ||
| Q3 25 | -353.4% | 37.6% | ||
| Q2 25 | -292.3% | 37.3% | ||
| Q1 25 | -2921.4% | 28.4% | ||
| Q4 24 | — | 43.2% | ||
| Q3 24 | -264.2% | 24.3% | ||
| Q2 24 | -390.6% | 22.8% | ||
| Q1 24 | -737.8% | 17.6% |
| Q4 25 | 7.2% | 17.9% | ||
| Q3 25 | -346.6% | 15.7% | ||
| Q2 25 | -287.1% | 15.5% | ||
| Q1 25 | -2911.4% | 9.4% | ||
| Q4 24 | — | 21.1% | ||
| Q3 24 | -259.6% | 5.4% | ||
| Q2 24 | -382.7% | 4.5% | ||
| Q1 24 | -719.1% | 1.2% |
| Q4 25 | $0.05 | $0.16 | ||
| Q3 25 | $-0.07 | $0.13 | ||
| Q2 25 | $-0.09 | $0.12 | ||
| Q1 25 | $-0.17 | $0.06 | ||
| Q4 24 | — | $0.17 | ||
| Q3 24 | $-0.17 | $0.03 | ||
| Q2 24 | $-0.20 | $0.02 | ||
| Q1 24 | $-0.25 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $1.5M |
| Total DebtLower is stronger | — | $361.1M |
| Stockholders' EquityBook value | $26.4M | $285.2M |
| Total Assets | $42.2M | $759.1M |
| Debt / EquityLower = less leverage | — | 1.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $1.5M | ||
| Q3 25 | $11.7M | $1.9M | ||
| Q2 25 | $27.5M | $1.1M | ||
| Q1 25 | $13.1M | $639.0K | ||
| Q4 24 | $22.5M | $1.8M | ||
| Q3 24 | $32.4M | $970.0K | ||
| Q2 24 | $30.0M | $1.7M | ||
| Q1 24 | $41.0M | $1.9M |
| Q4 25 | — | $361.1M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $328.8M | ||
| Q1 25 | — | $306.7M | ||
| Q4 24 | — | $296.7M | ||
| Q3 24 | $1.0M | $277.0M | ||
| Q2 24 | $2.0M | $273.7M | ||
| Q1 24 | $3.0M | $247.6M |
| Q4 25 | $26.4M | $285.2M | ||
| Q3 25 | $13.2M | $273.9M | ||
| Q2 25 | $18.2M | $250.8M | ||
| Q1 25 | $6.6M | $245.5M | ||
| Q4 24 | $17.5M | $251.3M | ||
| Q3 24 | $25.4M | $245.6M | ||
| Q2 24 | $21.6M | $245.5M | ||
| Q1 24 | $30.0M | $248.1M |
| Q4 25 | $42.2M | $759.1M | ||
| Q3 25 | $31.6M | $735.2M | ||
| Q2 25 | $40.7M | $689.8M | ||
| Q1 25 | $22.3M | $654.0M | ||
| Q4 24 | $32.2M | $646.8M | ||
| Q3 24 | $44.8M | $615.1M | ||
| Q2 24 | $42.3M | $608.2M | ||
| Q1 24 | $54.0M | $584.1M |
| Q4 25 | — | 1.27× | ||
| Q3 25 | — | 1.27× | ||
| Q2 25 | — | 1.31× | ||
| Q1 25 | — | 1.25× | ||
| Q4 24 | — | 1.18× | ||
| Q3 24 | 0.04× | 1.13× | ||
| Q2 24 | 0.09× | 1.11× | ||
| Q1 24 | 0.10× | 1.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $44.5M |
| Free Cash FlowOCF − Capex | — | $37.6M |
| FCF MarginFCF / Revenue | — | 144.5% |
| Capex IntensityCapex / Revenue | 0.0% | 26.7% |
| Cash ConversionOCF / Net Profit | -0.68× | 9.59× |
| TTM Free Cash FlowTrailing 4 quarters | — | $65.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $44.5M | ||
| Q3 25 | $-9.0M | $10.9M | ||
| Q2 25 | $-3.4M | $11.4M | ||
| Q1 25 | $-8.2M | $10.8M | ||
| Q4 24 | $-36.3M | $33.5M | ||
| Q3 24 | $-7.5M | $8.0M | ||
| Q2 24 | $-10.0M | $9.9M | ||
| Q1 24 | $-9.8M | $6.4M |
| Q4 25 | — | $37.6M | ||
| Q3 25 | — | $8.8M | ||
| Q2 25 | $-3.4M | $9.1M | ||
| Q1 25 | $-8.3M | $10.2M | ||
| Q4 24 | $-36.4M | $30.7M | ||
| Q3 24 | $-7.5M | $7.4M | ||
| Q2 24 | $-10.0M | $8.9M | ||
| Q1 24 | $-9.8M | $5.8M |
| Q4 25 | — | 144.5% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | -116.5% | 38.8% | ||
| Q1 25 | -1976.7% | 45.9% | ||
| Q4 24 | -2309.3% | 143.8% | ||
| Q3 24 | -225.7% | 37.6% | ||
| Q2 24 | -376.2% | 49.4% | ||
| Q1 24 | -573.0% | 33.6% |
| Q4 25 | 0.0% | 26.7% | ||
| Q3 25 | 0.0% | 8.9% | ||
| Q2 25 | 0.9% | 10.1% | ||
| Q1 25 | 35.6% | 3.0% | ||
| Q4 24 | 4.2% | 13.0% | ||
| Q3 24 | 0.0% | 3.2% | ||
| Q2 24 | 0.4% | 5.4% | ||
| Q1 24 | 3.2% | 3.5% |
| Q4 25 | -0.68× | 9.59× | ||
| Q3 25 | — | 2.87× | ||
| Q2 25 | — | 3.16× | ||
| Q1 25 | — | 5.20× | ||
| Q4 24 | — | 7.44× | ||
| Q3 24 | — | 7.48× | ||
| Q2 24 | — | 12.10× | ||
| Q1 24 | — | 31.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
PSTL
Segment breakdown not available.
